Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone650-243-6300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$92.01 million
Profitability
Miscellaneous
Employees270
Next Earnings Date4/30/2019 (Confirmed)
OptionableOptionable
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) posted its earnings results on Monday, October, 29th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.13. The biotechnology company had revenue of $23.47 million for the quarter, compared to analyst estimates of $21.52 million. Veracyte had a negative net margin of 25.00% and a negative return on equity of 42.80%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What guidance has Veracyte issued on next quarter's earnings?
Veracyte updated its FY 2019 earnings guidance on Monday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $113-117 million, compared to the consensus revenue estimate of $109.43 million.
What price target have analysts set for VCYT?
4 equities research analysts have issued 1-year price objectives for Veracyte's shares. Their forecasts range from $11.00 to $17.00. On average, they expect Veracyte's stock price to reach $13.4333 in the next year. This suggests that the stock has a possible downside of 41.7%. View Analyst Price Targets for Veracyte.
What is the consensus analysts' recommendation for Veracyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.
Has Veracyte been receiving favorable news coverage?
Media stories about VCYT stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Veracyte earned a news impact score of 1.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), PotNetwork (POTN), Miragen Therapeutics (MGEN), Psychemedics (PMD), Biocept (BIOC), First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI) and Cancer Genetics (CGIX).
What other stocks do shareholders of Veracyte own?
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
- Mr. Christopher M. Hall, Pres & COO (Age 50)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 60)
- Mr. Ashish Kheterpal, Chief Information Officer
Who are Veracyte's major shareholders?
Veracyte's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Strs Ohio (0.08%) and First Hawaiian Bank (0.06%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy and Jesse I Treu. View Institutional Ownership Trends for Veracyte.
Which institutional investors are selling Veracyte stock?
VCYT stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio and First Hawaiian Bank. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Giulia C Kennedy and Jesse I Treu. View Insider Buying and Selling for Veracyte.
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $23.03.
How big of a company is Veracyte?
Veracyte has a market capitalization of $946.74 million and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.
What is Veracyte's official website?
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
